Kornimate/medical-research-clean huggingface dataset:
cefepime vs ceftazidime as empirical therapy for neutropenic fever

Conditions: Neutropenia, Febrile; Leukemia; Pediatric Cancer; Antibiotic Reaction

Summary: empirical antibiotic therapy has been known to reduce the mortality and morbidity rate in neutropenic fever. until now, ceftazidime was the first line choice of neutropenic fever. however, resistance against ceftazidime has been reported. several countries have reported cefepime in reducing fever and shorten the length of hospitalization better than ceftazidime. this study is aimed to compare the effectivity of ceftazidime and cefepime to reduce fever and to increase the absolute neutrophils count (anc) in the first 72 hours.

this study is a randomized controlled trial with single blinding, conducted in the children's hematology-oncology wards of cipto mangunkusumo hospital and harapan kita children's hospital in jakarta, december 2018 through may 2019. study population includes all children with leukemia with febrile neutropenia episodes that are being hospitalized in our hospitals in the appropriate time. subjects were chosen by consecutive sampling. inclusion criteria includes children with leukemia aged 1 month to 18 years old undergoing chemotherapy, having fever of ≥ 38,3 degree celsius in axillar temperature with anc \< 1000/mm3. patients' parents or guardians must be willing to participate and willing to sign a written informed consent form. exclusion criteria includes patients with a history of penicillin or cephalosporin allergy and/or patients with kidney dysfunction. block randomization was done to place each patient into cefepime or ceftazidime group. data analysis was done using spss ver. 21 software. numerical data was shown as mean with standard deviation if the data is normally distributed or median with minimum-maximum value if the data is not normally distributed. chi-square as the correlation test was done in order to determine the association between free and dependent variables, based on nominal data. mann whitney test was done as the correlation test in order to test the difference between medians of uncoupled groups and one categorical variable, and one interval variable and the not normally distributed data.

Eligibility criteria:
inclusion criteria: * children with leukemia aged 1 month to 18 years old undergoing chemotherapy * having fever of ≥ 38,3 0c in axillar temperature * anc \< 1000/mm3 * patients' parents or guardians must be willing to participate and willing to sign a written informed consent form exclusion criteria: * patients with a history of penicillin or cephalosporin allergy * patients with kidney dysfunction

Keywords: fever neutropenia temperature absolute neutrophil count antibiotic
high-protein oral supplement improves normalized protein catabolic rate and inflammation markers

Conditions: Renal Failure; Chronic Kidney Disease Requiring Chronic Dialysis

Summary: the investigators propose to determine the impact of high-protein beverages on protein status and inflammation markers among ckd patients undergoing hemodialysis. a 12-week double-blind randomized cross-over trial will be used in which participants (n=22) will consume a 4-ounce high protein supplement with either whey (20 g total protein) or soy (20 g total protein). outcomes of interest include serum urea nitrogen and inflammation markers (crp and il-6). the findings will contribute to the knowledge gap regarding the effect of different protein types in ckd populations which can be translated to the development of affordable supplements to prevent malnutrition in adults with non-communicable diseases.


Eligibility criteria:
inclusion criteria: * 18 years old or older * diagnosed with stage 5 ckd for at least 3 months prior to the starting date of the trial * 3 sessions of hemodialysis per week for at least three months prior to the starting date of the trial * all participants have the ability to provide signed informed consent * have not been newly diagnosed * not present with symptomatic infection of covid-19 * have no dietary restriction * no food allergies * no chewing/swallowing difficulties exclusion criteria: * ckd patient stages 1-4. * ckd patient undergoing peritoneal hemodialysis. * in isolation due to covid-19 or other infectious disease * adult pregnant and/or lactating for the duration of the study. * any other renal disease autoimmune or otherwise. * use of other ip within 3 months prior of the eligibility screening.
a clinical trail of acupuncture and liu-zi-jue exercise for dysphagia in post-stroke

Conditions: Stroke

Summary: the traditional chinese medicine rehabilitation for post-stroke dysphagia impairment will be intervened, which can promote the recovery of dysphagia function of stroke patients, reduce the disability rate and improve the quality of life.

this study will collect inpatients from april 2020 to december 2022 who from the third affiliated hospital of zhejiang university of traditional chinese medicine, jiaxing hospital of traditional chinese medicine, hangzhou hospital of traditional chinese medicine.this study sets strict time window (stroke recovery, 30-180 days), use multi-center, large sample, randomized controlled study method and the objective recognition rehabilitation evaluation criteria and efficacy evaluation system to evaluate the clinical effect and analysis of health economics.

Eligibility criteria:
inclusion criteria: * dysphagia * meet the diagnostic criteria of stroke in traditional chinese medicine; * meet the diagnostic criteria of ischemic stroke in western medicine; * meet the diagnostic criteria of pseudobulbar palsy; * age is 18-85, gender not limited; * the course of disease is 30 to 180 days; * water test level 3 and level 3 above; * meet the requirements for indications of acupuncture and moxibustion techniques; volunteer to participate in this project, the patient has no serious complications, can accept acupuncture treatment and good compliance; * sign informed consent * moca（montreal cognitive assessment） score above 15. exclusion criteria: * dysphagia * patients with true bulbar palsy caused by brainstem encephalitis, motor neurone disease, pontine tumor, multiple sclerosis, myasthenia gravis, medulla bulbar cavity; * cerebral hemorrhage caused by cerebrovascular malformation, trauma, aneurysm and other causes; * pregnant or lactating women; * patients with severe primary chronic diseases, severe dementia and cognitive impairment, serious language understanding disorders, and mental illness, including heart, liver, kidney and other viscera, as well as the endocrine system and hematopoietic system; * suffered from a variety of bleeding tendency diseases; * the patient to swallow contrast drug allergy; * patients who do not meet the inclusion criteria, do not have poor treatment compliance as prescribed, cannot judge the efficacy or incomplete data affect the judgment of efficacy and are not suitable for clinical observation;

Keywords: stroke dysphagia rehabilitation traditional chinese medicine
study to evaluate long-term safety of asn002 in subjects with moderate to severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a randomized open label study to evaluate the long term safety of asn002 in subjects with moderate to severe atopic dermatitis (ad).

this is a randomized open label study where subjects with moderate to severe atopic dermatitis will roll over from the phase 1 asn002ad-101 (nct03139981) and asn002ad-201 (nct03531957) ph2b study and be randomized to receive asn002 at 40mg, 60mg, or 80mg once daily for up to 24 months. this study will also characterize the pharmacokinetics of asn002 through blood sampling from subjects who consent.

Eligibility criteria:
inclusion criteria * subject with a history of moderate to severe atopic dermatitis who participated in the preceding asn002ad-201 and asn002ad-101 study * subject must be a candidate for prolonged open label asn002/gusacitinib treatment according to the investigator's judgment. * subject has been using an emollient daily for at least 1 week prior to day 1 and agrees to continue using that same emollient daily throughout the study. * men and women participating in the study must use medically acceptable birth control or total abstinence from sexual intercourse * subject is willing to participate and is capable of giving informed consent. note: consent must be obtained prior to any study-related procedures. * subjects must be willing to comply with all study procedures and must be available for the duration of the study. * subject has a body mass index (bmi) ≤ 38 kg/m2. exclusion criteria * subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study. * subject has clinically infected atopic dermatitis. * a serious uncontrolled condition including hypertension, history of tuberculosis, hepatitis b or c infection, immune deficiency, heart disease, heart conduction disorder, diverticulitis, diabetes, reflux disease requiring protocol pump inhibitor therapy, malabsorption syndrome, or cancer * subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments. * subject has a history of eczema herpeticum within 12 months, and/or a history of 2 or more episodes of eczema herpeticum in the past. * willing to comply with discontinuation of certain treatments for ad, as directed by the investigator.

Keywords: eczema
a prospective evaluation of open-angle glaucoma subjects on two topical hypotensive medications treated with one suprachoroidal stent

Conditions: Subject With Primary Open-angle Glaucoma (POAG)

Summary: the purpose of this study is to assess the efficacy and safety of one istent supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma.

the study assesses the efficacy and safety of one istent supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma.

Eligibility criteria:
inclusion criteria: * diagnosed with primary open-angle glaucoma (poag) * subjects on two topical hypotensive medications exclusion criteria: * traumatic, uveitic, neovascular, or angle closure glaucoma * fellow eye already enrolled

Keywords: open angle glaucoma surgery ocular hypertension eye diseases
sevoflurane and propofol anesthesia on postoperative delirium

Conditions: General Anesthesia; Geriatric Patient

Summary: delirium is defined as an acute onset and fluctuating course of mental status change with inattention and an altered level of consciousness. delirium in the postoperative period can be divided into emergence delirium and postoperative delirium, based on the time of onset (silverstein et al., 2007).postanaesthesia delirium is a frequent and potentially serious problem affecting the safety of patients and medical personnel. clinical studies demonstrated that postoperative delirium is associated with worse outcomes such as prolonged hospital stay, postdischarge institutionalization, and increased mortality (ely et al., 2004a; thomason et al., 2005; robinson et al., 2009). multiple factors may contribute to the development of postoperative delirium, including patient's medical condition, administration of anesthetics or analgesics and degree of operative stress (yildizeli et al., 2005; robinson \& eiseman, 2008; deiner \& silverstein, 2009). sevoflurane anesthesia have been reported to be associated with more emergence delirium in pediatric patients, when compared with propofol anesthesia. it is not clear if propofol anesthesia will benefit the geriatric patients on postoperative delirium, when compared with sevoflurane anesthesia. we hypothesize that propofol anesthesia will reduce the rate of postoperative delirium by 50% when compared with sevoflurane anesthesia.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status classification (asa_ps) class i-iii * aged 60 years or above * elective major surgery under general anesthesia exclusion criteria: * asa_ps\>=iv * aged under 60 yr old * body mass index (bmi) \>30 * neurologic disease * cardiac surgery and neurologic surgery * anticonvulsant drugs * chronic analgesics intake * participating in the investigation of another study

Keywords: postoperative delirium geriatric general anesthesia propofol sevoflurane
a phase ii clinical trial on comparison of effectiveness and safeness of different amifostine regimens

Conditions: Nasopharyngeal Neoplasms; Salivary Gland Diseases; Bone Marrow Diseases; Mucositis

Summary: rationale * radiotherapy is the primary therapeutic strategy for nasopharyngeal carcinoma. * radiotherapy may cause adverse effect such as xerostomia and mucositis. * amifostine has the ability of protecting the normal tissue but also has some side effects. purpose * this phase ii trial is to study the protecting effect and safety of different amifostine regimens in patients with nasopharyngeal carcinoma.

rationale: nasopharyngeal carcinoma is a kind of malignant tumor which is treated primarily by radiation therapy. this therapeutic strategy often causes adverse effects such as dysfunction of salivary gland and lesion of oral mucosa. with concurrent chemotherapy, it may also cause toxicity to kidney, bone marrow, and other organs or tissues. when administered prior to chemoradiotherapy, amifostine has been proved to has the ability of protecting the normal from these adverse effects so as to improve the patient tolerance. however, there are also some side effects of amifostine itself, such as nausea, vomiting and hypotension, especially when high dose is applied. purpose: this phase ii randomized controlled trial is to study the protecting effect and its safety of amifostine every-other-day regimen compared with standard everyday regimen on adverse effects such as myelosuppression, xerostomia and mucositis, in patients with nasopharyngeal carcinoma stage t1-t4, n0-n3, m0 and undergoing concurrent chemoradiotherapy.

Eligibility criteria:
inclusion criteria: * nasopharyngeal cancer patients diagnosed by pathology or cytology * uicc/ajcc 2010 stage t1-4 n0-3 m0 * male or female patients with age between 18 and 75 years old * karnofsky performance scores ≥ 60 * expected survival ≥ 3 months * without dysfunction of heart, lung, liver, kidney and hematopoiesis * no previous allergic reaction to the drug exclusion criteria: * history of alcohol or drug abuse within 3 months * pregnant or lactating women * currently under treatment with other similar drugs * anti-hypertension drugs applied in less than 24 hours * severe hypocalcemia * dysfunction of heart, lung, liver, kidney or hematopoiesis * severe neurological, mental or endocrine diseases * previous allergic reaction to the drug * patients participated in clinical trials of other drugs within last 3 months * other unsuitable reason

Keywords: nasopharyngeal carcinoma amifostine myelosuppression xerostomia mucositis
exploring the value of urine proteomics-based dynamic surveillance for early recurrence after radical surgery for hepatocellular carcinoma: a prospective cohort study

Conditions: Hepatocellular Carcinoma (HCC)

Summary: in this study, we explored and validated the predictive value of the longitudinal monitoring model of urinary proteomics for postoperative recurrence of hepatocellular carcinoma and the predictive value of minimal residual disease (mrd) status, verified whether it is earlier than the recurrence suggested by imaging tests, and initially explored its clinical feasibility in guiding the adjuvant treatment of hepatocellular carcinoma in the postoperative period, so as to provide a new idea for the strategy of early intervention in the postoperative period of hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * patients with hepatocellular carcinoma whose tumor stage at the time of initial diagnosis is consistent with bclc staging 0/stage a/stage b, who can undergo radical surgical resection, and who have not received other antitumor therapy preoperatively. exclusion criteria: * unable to provide specimens for testing such as urine proteomics; patients with a previous diagnosis of renal or urologic disease, two or more tumors at the same time; patients with non-primary foci of liver disease. previously received anti-tumor therapy such as targeted immunotherapy.

Keywords: urinary proteomics hepatocellular carcinoma recurrence after surgery
"online surveys" in perioperative knee anterior cruciate ligament (acl) reconstruction

Conditions: Anterior Cruciate Ligament Rupture

Summary: to monitor the quality of health care systems, patient-reported outcome measures (proms) should be collected and analyzed before and after medical interventions. the development of information technology and software along with an exponential increase in the use of the internet now allows new modalities for collecting proms. online survey has become one of the most popular methods of data collection. the hypothesis is that providing a "brace cold therapy" to patients undergoing knees surgeries will generate an increasing in response rate to online surveys.

in the setting of anterior cruciate ligament reconstruction (aclr), an alternative to standard clinic-based follow-up is used in our institution via the utilization of web-based follow-up platform (othense) that allows surgeons to monitor a patient's subjective quality of recovery, including symptoms of pain and limitations in activities of daily living. this tool has the potential to enhance quality of care by providing weekly updates about the patient's physical impairment. we started using it in 2018. from a single orthopedic surgeon, a total of 100 patients who were planned to undergo an aclr requiring formal post-operative follow-up were participated. the process began upon preop consultation, where the patient is offered a description of the survey and asked to use a link allowing direct access to the online surveys (orthense platform). • participants were divided in two groups : * first group: patients operated for aclr * second group: patients operated for aclr, and received a "knee brace cold therapy" to use it in the post op recovery rehabilitation, sent to patient's home directly during pre-op phase. a standardized follow-up protocol for both groups. the surveys included questions related to rehabilitation and questions from standard patient-reported-outcome-measures proms. they were asked to complete the following surveys pre-operatively and post-operatively: j -14 / j-7 / j -5/ j-2 / j+3 / j+7 / j+14 / j+21 / j+28 / j+35 / j+45 for both groups, data was collected for up to 6 weeks following surgery (j+45), for a total of 11 surveys

Eligibility criteria:
inclusion criteria: * patients performing knee surgeries (acl) * 6 weeks minimum of f/u (j+45) * in university hospital toulouse exclusion criteria: * f/u = 6 weeks
the sunnybrook dementia study

Conditions: Dementia

Summary: the prospect of disease-modifying therapies in the pipeline for alzheimer's disease (ad) has intensified efforts to use brain imaging more effectively for diagnosis and monitoring of dementing illnesses. there is also emerging awareness of the destructive interplay between ad and cerebrovascular disease (cvd) in our aging population; both disorders share common vascular risk factors and may respond to similar prevention treatments. brain mapping techniques capitalize on the fact that different neurodegenerative diseases target particular brain areas. brain shrinkage and stroke disease can be quantified on magnetic resonance imaging (mri) using computerized analysis. this ongoing study applies advanced mr imaging analysis, genetic testing and standardized cognitive and functional assessments done at yearly intervals to measure and monitor longitudinal change in patients with ad, vascular and other neurodegenerative diseases and potentially to measure modifying effects of emerging therapies. over 1700 patients (mild cognitive impairment or dementia from ad, vascular, frontotemporal or lewy body disease) and 140 normal elderly have already been enrolled, with 180 autopsies. this study utilizes specialized imaging analysis software packages to reliably quantify brain tissue volumes and small vessel disease, the most common type of cvd. the sds also investigates other potential biomarkers of dementia such as eye-tracking, optical coherence tomography, gait and balance, and the gut microbiome to explore their clinical utility. results from this study will help to improve diagnosis, to customize treatment, and to better monitor disease-modifying therapies currently under investigation should they become applicable to everyday practice.


Eligibility criteria:
patient inclusion criteria (general): * age between 40 and 90 (inclusive) * fluent in english * completed 8 years of education or higher * visual and auditory acuity adequate for neuropsychological testing * mini-mental state exam (mmse) score ≥ 16 patient exclusion criteria (general): * possible secondary causes of dementia, concomitant or history of neurological or psychiatric illness (other than stroke or parkinsonism) * history of alcohol or substance abuse or dependence within the past 2 years normal control inclusion criteria: * age between 40-90 * fluent in english * completed 8 years of education or higher * no significant memory complaints normal control exclusion criteria: * being treated or history of being treated for psychiatric or neurological illness * history of alcohol or substance abuse or dependence within the past 2 years * current use of psychoactive medications (e.g. antidepressant, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) * medical contraindications to mri

Keywords: neurodengeneration neuroimaging